SHOP NOW

about us

BEYOND BOUNDARIES

Who We Are

Visionary Innovation

We’re redefining what’s possible in medical device and life science markets.

The Disruptors

We are the disruptive technology providers applying bioactive and biomedical coatings on any surface.

Revolutionary Process

Originating from advanced semiconductor plasma technologies, our patented cold plasma process deposits nanometer-thin functional coatings—faster, cleaner, less expensive and more sustainably than ever before.

Unrivaled Quality

We deliver quality no one else can – period.

TheraDep Device coating a Microplate

Our Vision

Transforming Lives Through Life Science Innovations

Our Mission

To deliver a disruptive bioactive surface that dramatically enhances the well-being of our community

Our Values

  • We set high standards and measure success by results that matter.
  • We continuously improve our products, processes, and customer outcomes.
  • We execute with discipline, speed, and accountability.
  • We operate transparently and do what’s right—always.
  • We honor our commitments to customers, partners, and shareholders.
  • We take ownership, learn quickly, and act responsibly.
  • We innovate to solve real scientific and customer challenges.
  • We translate bioactive surface science into practical, scalable solutions.
  • We invest in ideas that deliver meaningful impact and long-term value.
  • Quality is designed into every material, process, and product.
  • We meet and exceed medical-grade and regulatory expectations.
  • Every product reflects our commitment to reliability, performance, and trust.
Our History

Company Timeline

15 Patented Idea
2015
Company Founded and granted US patents licensed
Founded in Clonmel, Ireland and Palo Alto, CA by Liam O’Neill (CTO) Pat Burt, and John O’Donoghue.
2016
First Patent & R&D Lab
R&D lab established in Clonmel, Ireland.
2017
Expanded IP & Preclinical Validation
First European patent issued and preclinical data published.
2018
Moved into New Lab in Ireland
First application of pharmaceutical coatings using plasma. Second European patent granted.
2019
CAP Platform Breakthrough
Initial Cold Atmospheric Plasma (CAP) machine built and successfully tested.
2021
Patent Portfolio Strengthens
Second US patent granted. First Japanese patent granted.
2022
Commercial Manufacturing Milestone
First production stent-coating machine shipped.
2023
Pipeline Expansion
Third US patent granted, and additional patents filed, extending platform coverage.
2025
Commercial Acceleration
New management team onboarded: Bryan Hoadley (CEO) & Richard Fernandes (COO)
Japanese, Chinese & Korean patents granted. Commercial projects engaged. Developed commercial microplate coating line.
2026
Strategic Expansion
Partnership with DSM-Firmenich announced
Launch of BioDep medical grade collagen-coated microplates